Group 1 - The company, Fuhong Hanlin (02696.HK), announced on August 29, 2023, that the board of directors resolved to grant a total of 67,500 stock options to 4 participants under the stock option plan [1] - Additionally, the company will grant a total of 87,500 restricted stock units to 8 participants under the restricted stock unit plan [1]

Group 1 - The company, Fuhong Hanlin (02696), announced that on August 29, 2025, the board of directors resolved to grant a total of 67,500 stock options to 4 participants under the stock option plan [1] - Additionally, the company will grant a total of 8,750 restricted stock units to 8 participants under the restricted stock unit plan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 授出購股權及受限制股份單位 A. 緒言 本公告乃根據上市規則第17.06A、17.06B及17.06C條作出。 於2025年8月29日，董事會決議根據購股權計劃向4名參與者授出合共67,500份購 股權及根據受限制股份單位計劃向8名參與者授出合共87,500份受限制股份單位。 B. 根據購股權計劃授出購股權 於2025年8月29日，董事會決議根據購股權計劃向4名參與者授出合共67,500份購 股權。授出購股權的條款如下： 授予日 ： 2025年8月29日 (iii) H股的面值人民幣1.00元。 1 承授人類別及授出的 購股權數目 ： 4 名僱員參與者（不包括董事）：合共67,500 份 購股權（代表可認購67,500股H股的權利，佔本 公告日 ...

Core Points - The company has announced the reappointment of several members to its board committees, effective from August 29, 2025 [1] - Wenjie Zhang has been reappointed as the chairman of the board, with his term starting on August 29, 2025, until the end of the fourth board term [2] - Zhu Jun has been reappointed as the CEO, effective from August 29, 2025, and will continue to lead the management team [2] Board Committees Summary - Su Deyang, Chen Liyuan, and Guan Xiaohui have been reappointed as members of the Audit Committee, with Su Deyang serving as the chairman [1] - Yihao Zhang has been appointed, and Wenjie Zhang, Guan Xiaohui, Su Deyang, and Song Ruilin have been reappointed to the Nomination Committee, with Wenjie Zhang as the chairman [1] - Chen Yuqing has been appointed, and Song Ruilin and Chen Liyuan have been reappointed to the Compensation Committee, with Song Ruilin as the chairman [1] - Chen Yuqing and Liu Yi have been appointed, and Wenjie Zhang, Zhu Jun, Chen Qiyu, Xingli Wang, Su Deyang, and Song Ruilin have been reappointed to the Strategy Committee, with Wenjie Zhang as the chairman [1] - Chen Liyuan, Su Deyang, Song Ruilin, Wenjie Zhang, and Zhu Jun have been reappointed to the Environmental, Social, and Governance Committee, with Chen Liyuan as the chairman [1] - Wu Yifang, Wen Deyong, and Zhao Guoping have retired from their positions as non-executive and independent non-executive directors and will no longer serve on the relevant board committees [1]

上海復宏漢霖生物技術股份有限公司 經修訂及重列之章程 （經公司於2025年8月29日舉行的股東會審議通過） | 目錄 | | --- | | 第一章 | 總則 | | 1 | | --- | --- | --- | --- | | 第二章 | | 經營宗旨和範圍 | 4 | | 第三章 | 股份 | | 4 | | 第一節 | | 股份發行 | 4 | | 第二節 | 股份增減和回購 | | 5 | | 第三節 | | 股份轉讓 | 6 | | 第四節 | | 購買公司股份的財務資助 | 7 | | 第四章 | | 股東和股東會 | 7 | | 第一節 | 股東和股東名冊 | | 7 | | 第二節 | 股東會的一般規定 | | 12 | | 第三節 | | 股東會的召集 | 13 | | 第四節 | | 股東會的提案與通知 | 14 | | 第五節 | | 股東會的召開 | 15 | | 第六節 | | 股東會的表決和決議 | 18 | | 第五章 | 董事會 | | 20 | | 第一節 | | 董事 | 20 | | 第二節 | 獨立非執行董事 | | 21 | | 第三節 | | 董事會 | 21 | ...

董事名單與其角色及職能 董事名單與其角色及職能 董事會（「董事會」）成員載列如下： 董事會主席 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 相關董事會委員會成員載列如下： | | | | | | 環境、社會 及 | | --- | --- | --- | --- | --- | --- | | 董事 | 審計委員會 | 薪酬委員會 | 提名委員會 | 戰略委員會 | 管治委員會 | | Wenjie Zhang先生 | | | C | C | M | | 朱俊博士 | | | | M | M | | 陳啟宇先生 | | | | M | | | 陳玉卿先生 | | M | | M | | | 關曉暉女士 | M | | M | | | | 劉毅博士 | | | | M | | | Xing ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 重新委任首席執行官 上海復宏漢霖生物技術股份有限公司（「本公司」，與其附屬公司統稱「本集團」）董 事（「董事」）會（「董事會」）欣然宣佈於2025年8月29日（星期五）下午四時正假座 中國上海市徐匯區宜州路188號B8幢10樓會議室舉行的2025年第三次臨時股東會 （「臨時股東會」）之投票結果。 茲提述本公司日期為2025年8月12日之臨時股東會通告及有關臨時股東會的通函 （「通函」）及本公司日期為2025年8月15日有關臨時股東會的公告。除文義另有所 指外，本公告所用詞彙與通函所界定者具有相同涵義。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 於2025年8月29日（星期五）舉行的 2025年第三次臨時股東會 所提呈決議案之投票結果 董事會專門委員會組成 重新委任董事會主席、監事會主席 ...

Core Viewpoint - The company, Fuhong Hanlin (02696), has seen a significant stock price increase following the announcement of successful clinical trials for its drug HLX43, indicating strong potential in the lung cancer treatment market [1] Group 1: Clinical Developments - Fuhong Hanlin has completed the first patient dosing in the U.S. for the international multicenter phase II clinical study of HLX43, a PD-L1 targeted antibody-drug conjugate for advanced non-small cell lung cancer (NSCLC) patients [1] - The company has had 10 lung cancer studies accepted for presentation at the 2025 World Conference on Lung Cancer (WCLC), focusing on three core innovative drugs: anti-PD-1 monoclonal antibody H drug, anti-EGFR monoclonal antibody HLX07, and the first PD-L1 ADC HLX43 entering phase II clinical trials globally [1] Group 2: Market Potential - Citigroup has indicated that Fuhong Hanlin will soon present the latest data on HLX43 at WCLC, which could further demonstrate its potential in treating NSCLC [1] - If HLX43 maintains an objective response rate (ORR) of 35% to 40% and a median progression-free survival (mPFS) of approximately 5.5 months in larger samples, the data will be highly persuasive [1]

Group 1 - The core viewpoint of the article highlights the positive market response to Fuhong Hanlin's recent clinical developments, with the stock price increasing over 8% during trading and closing at 77.95 HKD, reflecting a 5.34% gain [1] - Fuhong Hanlin has completed the first patient dosing in the U.S. for its HLX43, a PD-L1 antibody-drug conjugate, in a Phase II clinical trial for advanced non-small cell lung cancer (NSCLC) [1] - The company is evolving into an innovative biopharmaceutical firm centered around HLX43, as indicated by the cash flow generated from its biosimilars in China and globally [1] Group 2 - Fuhong Hanlin has had 10 lung cancer studies accepted for presentation at the 2025 World Conference on Lung Cancer (WCLC), focusing on three core innovative drugs: anti-PD-1 monoclonal antibody H drug, anti-EGFR monoclonal antibody HLX07, and the PD-L1 ADC HLX43 [1] - Citigroup anticipates that Fuhong Hanlin will present the latest data on HLX43 at WCLC, which could further demonstrate its potential in treating NSCLC [1] - If HLX43 maintains an objective response rate (ORR) of 35% to 40% and a median progression-free survival (mPFS) of approximately 5.5 months in larger samples, the data will be highly persuasive [1]

Core Viewpoint - Fosun Pharma is undergoing a critical phase of innovation transformation, with mixed financial results in the first half of 2025, showing a slight decline in revenue but significant growth in net profit [1][3]. Financial Performance - The company's revenue for the first half of 2025 was 19.514 billion yuan, a decrease of 4.63% compared to the same period last year [2]. - The net profit attributable to shareholders was 1.701 billion yuan, an increase of 38.96% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 960 million yuan, down 23.39% year-on-year [2]. - The net cash flow from operating activities was 2.134 billion yuan, an increase of 11.90% [2]. - As of the end of the reporting period, the net assets attributable to shareholders were 47.398 billion yuan, a slight increase of 0.29% [2]. Strategic Focus - The new leadership under Chairman Chen Yuqing has not altered the company's established strategy, which continues to focus on the "4 IN Strategy" (Innovation, Internationalization, Integration, and Intelligence) [4]. - The company is in a transitional phase, with a 5.29% decline in pharmaceutical business revenue to 13.901 billion yuan, while innovative drug revenue exceeded 4.3 billion yuan, growing by 14.26% [4]. Research and Development - Fosun Pharma invested 2.584 billion yuan in R&D during the first half of 2025, with three mature R&D entities focusing on different therapeutic areas [5]. - The company is positioning itself in the high-barrier nuclear medicine sector by establishing a new platform company for nuclear medicine products [6]. International Expansion - Overseas business is expected to be a significant support for future performance, with revenue from international markets reaching 5.478 billion yuan, accounting for 28.07% of total revenue [8]. - The company is expanding its presence in emerging markets such as the Middle East and Southeast Asia, leveraging local partnerships and registrations [8]. Asset Management - Fosun Pharma has been actively divesting non-core assets, with total signed disposal projects exceeding 2 billion yuan in 2025 [9]. - The company increased its stake in its subsidiary, Fosun Hani, from 59.56% to 63.43% by acquiring additional shares [10].